SPDA1
MCID: SPN225
MIFTS: 74

Spondyloarthropathy 1 (SPDA1)

Categories: Bone diseases, Genetic diseases, Muscle diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Spondyloarthropathy 1

MalaCards integrated aliases for Spondyloarthropathy 1:

Name: Spondyloarthropathy 1 57 74 38
Ankylosing Spondylitis 57 12 75 53 25 74 37 29 6 43 15 17 72 33
Spondyloarthropathy, Susceptibility to, 1 57 13 40
Marie-Strumpell Spondylitis 57 53 74
Bechterew Syndrome 57 53 74
Spondylarthritis Ankylopoietica 25 74
Spondylitis, Ankylosing 25 44
Reiter Syndrome 74 72
Spda1 57 74
Ankylosing Spondylitis, Susceptibility to 57
Spondyloarthritis Ankylopoietica 25
Ankylosing Spondyloarthritis 53
Ankylosing Spondylarthritis 74
Spondylitis Ankylopoietica 25
Marie-Struempell Disease 25
Marie-Strumpell Disease 12
Rheumatoid Spondylitis 74
Spondylitis Ankylosans 74
Spondylitis Ankylosing 55
Spondylarthropathies 72
Arthritis, Psoriatic 72
Psoriatic Arthritis 74
Bekhterev's Disease 12
Arthritis, Reactive 72
Reactive Arthritis 74
Bekhterev Syndrome 12
Bechterew Disease 25
As 25

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
overall prevalence is between 0.5 and 14 per 100,000 people per year
genetic heterogeneity (see spondyloarthropathy, susceptibility to, 2 )
spondyloarthropathy includes a spectrum of related disorders, including, 1 - ankylosing spondylitis (as), 2 - a subset of psoriatic arthritis (psa), 3 - reactive arthritis (rea), 4 - arthritis associated with inflammatory bowel disease (aibd), 5 - undifferentiated spondyloarthropathy (uspa)


HPO:

32
spondyloarthropathy 1:
Inheritance multifactorial inheritance heterogeneous


Classifications:



External Ids:

Disease Ontology 12 DOID:7147
KEGG 37 H01674
ICD9CM 35 720.0
NCIt 50 C84564
SNOMED-CT 68 9631008
ICD10 33 M45
UMLS 72 C0003872 C0035012 C0038013 more

Summaries for Spondyloarthropathy 1

Genetics Home Reference : 25 Ankylosing spondylitis is a form of ongoing joint inflammation (chronic inflammatory arthritis) that primarily affects the spine. This condition is characterized by back pain and stiffness that typically appear in adolescence or early adulthood. Over time, back movement gradually becomes limited as the bones of the spine (vertebrae) fuse together. This progressive bony fusion is called ankylosis. The earliest symptoms of ankylosing spondylitis result from inflammation of the joints between the pelvic bones (the ilia) and the base of the spine (the sacrum). These joints are called sacroiliac joints, and inflammation of these joints is known as sacroiliitis. The inflammation gradually spreads to the joints between the vertebrae, causing a condition called spondylitis. Ankylosing spondylitis can involve other joints as well, including the shoulders, hips, and, less often, the knees. As the disease progresses, it can affect the joints between the spine and ribs, restricting movement of the chest and making it difficult to breathe deeply. People with advanced disease are also more prone to fractures of the vertebrae. Ankylosing spondylitis affects the eyes in up to 40 percent of cases, leading to episodes of eye inflammation called acute iritis. Acute iritis causes eye pain and increased sensitivity to light (photophobia). Rarely, ankylosing spondylitis can also cause serious complications involving the heart, lungs, and nervous system.

MalaCards based summary : Spondyloarthropathy 1, also known as ankylosing spondylitis, is related to juvenile rheumatoid arthritis and exanthem, and has symptoms including pain, stiffness in the spine and stiffness in the neck. An important gene associated with Spondyloarthropathy 1 is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Antigen processing and presentation and Innate Immune System. The drugs Tazarotene and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are kyphosis and arrhythmia

Disease Ontology : 12 A bone inflammation disease that results in inflammation in the joints of the spine and pelvis. The disease has symptom pain, has symptom stiffness in the spine, has symptom stiffness in the neck, has symptom stiffness in the hips, has symptom stiffness in the jaw and has symptom stiffness in the rib cage.

NIH Rare Diseases : 53 Ankylosing spondylitis (AS) is a type of chronic, inflammatory arthritis that mainly affects the spine. It usually begins with inflammation of the joints between the pelvic bones and spine, gradually spreading to the joints between the vertebrae. Signs and symptoms usually begin in adolescence or early adulthood and may include back pain and stiffness. Back movement gradually becomes more limited as the vertebrae fuse together. The condition may also affect the shoulders; ribs; hips; knees; and feet; as well as the eyes; bowel; and very rarely, the heart and lungs. AS is likely caused by a combination of genetic and environmental factors; variations in several genes are thought to affect the risk to develop AS. In most cases, treatment involves exercise and medications to relieve pain and inflammation.

OMIM : 57 Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS), a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard et al., 2004). These phenotypes are difficult to differentiate because they may occur simultaneously or sequentially in the same patient. Studies have suggested that a predominant shared component, including HLA-B27, predisposes to all phenotypic subsets, and that these subsets should be considered as various phenotypic expressions of the same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper (2007) provided a detailed review of ankylosing spondylitis, including clinical features, pathogenesis, and management. (106300)

MedlinePlus : 43 Ankylosing spondylitis is a type of arthritis of the spine. It causes inflammation between your vertebrae, which are the bones that make up your spine, and in the joints between your spine and pelvis. In some people, it can affect other joints. AS is more common and more severe in men. It often runs in families. The cause is unknown, but it is likely that both genes and factors in the environment play a role. Early symptoms of AS include back pain and stiffness. These problems often start in late adolescence or early adulthood. Over time, AS can fuse your vertebrae together, limiting movement. Some people have symptoms that come and go. Others have severe, ongoing pain. A diagnosis of AS is based on your medical history and a physical examination. You may also have imaging or blood tests. AS has no cure, but medicines can relieve symptoms and may keep the disease from getting worse. Eating a healthy diet, not smoking, and exercising can also help. In rare cases, you may need surgery to straighten the spine. NIH: National Institute of Arthritis and Musculoskeletal and Skin Disease

KEGG : 37
Ankylosing spondylitis (AS), formerly also known as Bechterew's disease, is a rheumatic disease of the axial skeleton that mainly affects the spine and the sacroiliac joint in the pelvis. AS is one of a group of inflammatory diseases, called spondyloarthritides, which share features. This disease is characterized by erosion, sclerosis, and ossification, which may result in complete fusion and rigidity of the spine. Regarding extra-articular manifestations, the most frequent is anterior uveitis. The major functional losses occur during the first 10 years of disease. It usually begins in the second or third decade of life, preferentially in HLA-B27-positive Caucasian males. Its etiology and pathogenesis are not completely understood, but the most prevalent hypothesis involves immune mediation as its major mechanism, including several cytokines. To date, more than 40 genetic variants have been identified that influence the risk of developing AS, including HLA alleles such as HLA-B27. Non-steroid anti-inflammatory drugs (NSAIDs) are used to reduce pain and inflammation. Additional disease-modifying anti-rheumatic drugs (DMARDs) are prescribed to slowdown disease progression. The most frequently applied biological agents approved for AS are TNF alpha inhibitors. The IL-17 inhibitor secukinumab has been recently approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and AS.

UniProtKB/Swiss-Prot : 74 Spondyloarthropathy 1: A chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.

Wikipedia : 75 Ankylosing spondylitis (AS) is a type of arthritis in which there is a long-term inflammation of the... more...

Related Diseases for Spondyloarthropathy 1

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 10619)
# Related Disease Score Top Affiliating Genes
1 juvenile rheumatoid arthritis 32.3 TNFRSF1B TNF CRP
2 exanthem 32.1 TNFRSF1B TNF CRP
3 mycoplasma pneumoniae pneumonia 32.1 TNF IL17A CRP
4 kawasaki disease 32.1 TNF MMP3 CRP
5 rubella 32.1 TNF HLA-B CD40LG
6 cytomegalovirus infection 32.1 TNF HLA-B B2M
7 myocarditis 32.0 TNF HLA-B CD40LG
8 toxoplasmosis 31.9 TNF TLR4 CD40LG
9 cystitis 31.9 TNF TLR4 CRP
10 drug reaction with eosinophilia and systemic symptoms 31.9 TNF HLA-B CRP
11 post-transplant lymphoproliferative disease 31.9 TNFRSF1B TNF B2M
12 pyelonephritis 31.8 TNF TLR4 CRP
13 trench fever 31.8 TNF TLR4
14 alveolar echinococcosis 31.8 TNF TLR4 HLA-B
15 sarcoidosis 1 31.8 TNFRSF1B TNF NOD2
16 lyme disease 31.8 TNF IL17A CRP CD40LG
17 vasculitis 31.8 TNFRSF1B TNF HLA-B CRP CD40LG
18 septic arthritis 31.8 TLR4 MMP3 CRP
19 atherosclerosis susceptibility 31.7 TNF TLR4 CRP
20 typhoid fever 31.7 TNF TLR4 CRP
21 pneumonia 31.7 TNF TLR4 CRP CD40LG
22 hidradenitis suppurativa 31.6 TNF NOD2 IL17A
23 takayasu arteritis 31.5 TNF MMP3 HLA-B CRP
24 chorioamnionitis 31.5 TNF TLR4 CRP
25 proteasome-associated autoinflammatory syndrome 1 31.5 TNF TLR4 IL17A CRP
26 discitis 31.5 MRAP CRP
27 tenosynovitis 31.5 TNFRSF1B MRAP CRP
28 echinococcosis 31.5 TNF TLR4 IL17A HLA-B
29 lymphadenitis 31.5 TNF TLR4 NOD2
30 familial mediterranean fever 31.5 TNF NOD2 CRP
31 reactive arthritis 31.5 TNF IL17A HLA-B CRP
32 mycobacterium tuberculosis 1 31.5 TNFRSF1B TNF TLR4 IL17A
33 pelvic inflammatory disease 31.4 TLR4 CRP CD40LG
34 brucellosis 31.4 TNF TLR4 CRP CD40LG
35 pyelitis 31.4 TLR4 CRP B2M
36 q fever 31.4 TNF TLR4 NOD2
37 urinary system disease 31.3 TNF CRP B2M
38 peritonitis 31.3 TNF CRP B2M
39 acquired immunodeficiency syndrome 31.3 TNF HLA-B B2M
40 ileocolitis 31.3 TNF NOD2
41 melkersson-rosenthal syndrome 31.2 TNFRSF1B TNF NOD2
42 cholangitis 31.2 TNF HLA-B CRP
43 langerhans cell histiocytosis 31.1 TNFSF11 IL17A CD163
44 mesenteric lymphadenitis 31.1 NOD2 MRAP CRP
45 prosthetic joint infection 31.1 TNFRSF11B TLR4
46 uremia 31.1 TNFRSF11B CRP B2M
47 pustulosis of palm and sole 31.1 TNFRSF1B TNF MRAP
48 pyuria 31.1 MRAP CRP
49 aggressive periodontitis 31.1 TNFSF11 TNF TLR4
50 chlamydia 31.0 TNF TLR4 CRP

Comorbidity relations with Spondyloarthropathy 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential Osteoporosis
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Spondyloarthropathy 1:



Diseases related to Spondyloarthropathy 1

Symptoms & Phenotypes for Spondyloarthropathy 1

Human phenotypes related to Spondyloarthropathy 1:

32 (show all 10)
# Description HPO Frequency HPO Source Accession
1 kyphosis 32 HP:0002808
2 arrhythmia 32 HP:0011675
3 psoriasiform dermatitis 32 HP:0003765
4 inflammation of the large intestine 32 HP:0002037
5 back pain 32 HP:0003418
6 aortic regurgitation 32 HP:0001659
7 anterior uveitis 32 HP:0012122
8 enthesitis 32 HP:0100686
9 hip osteoarthritis 32 HP:0008843
10 sacroiliac arthritis 32 HP:0012317

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
anterior uveitis

Abdomen Gastrointestinal:
inflammatory bowel disease (crohn disease and ulcerative colitis)

Skeletal Pelvis:
arthritis (hip)

Skin Nails Hair Skin:
psoriasis

Cardiovascular Heart:
aortic insufficiency
aortitis
cardiac conduction abnormalities

Skeletal Spine:
accentuated kyphosis
back stiffness
nocturnal back pain
ankylosing spondylitis
sacroiliitis
more
Skeletal Limbs:
peripheral arthritis (oligoarticular or polyarticular)
peripheral enthesitis

Laboratory Abnormalities:
hla-b27 haplotype association (95% patients)
rheumatoid factor negative

Clinical features from OMIM:

106300

Symptoms:

12
  • pain
  • stiffness in the spine
  • stiffness in the neck
  • stiffness in the hips
  • stiffness in the jaw
  • stiffness in the rib cage

UMLS symptoms related to Spondyloarthropathy 1:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Spondyloarthropathy 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 ANKH B2M CD163 CD40LG IL17A MMP3
2 homeostasis/metabolism MP:0005376 10.03 ANKH B2M CD163 CD40LG CRP IL17A
3 cardiovascular system MP:0005385 10.02 ANKH B2M CD163 CD40LG CRP TLR4
4 immune system MP:0005387 10 ANKH B2M CD163 CD40LG CRP IL17A
5 respiratory system MP:0005388 9.5 ANKH CD163 IL17A TLR4 TNF TNFRSF1B
6 skeleton MP:0005390 9.32 ANKH CD40LG IL17A MMP3 NOD2 TLR4

Drugs & Therapeutics for Spondyloarthropathy 1

Drugs for Spondyloarthropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Hydroxychloroquine Approved Phase 4 118-42-3 3652
4
Aceclofenac Approved, Investigational Phase 4 89796-99-6
5
Pamidronate Approved Phase 4 40391-99-9 4674
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Certolizumab pegol Approved Phase 4 428863-50-7
8
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
9
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
10
tannic acid Approved Phase 4 1401-55-4
11
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Atorvastatin Approved Phase 4 134523-00-5 60823
15
carbamide peroxide Approved Phase 4 124-43-6
16 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
17
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
18
Tofacitinib Approved, Investigational Phase 4 477600-75-2
19
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
20
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Etanercept Approved, Investigational Phase 4 185243-69-0
23
Acetaminophen Approved Phase 4 103-90-2 1983
24
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
25
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
26
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
27
Loxoprofen Investigational Phase 4 68767-14-6, 80382-23-6 3965
28 Natriuretic Peptide, Brain Phase 4
29 Natriuretic Agents Phase 4
30 Vitamin B3 Phase 4
31 Keratolytic Agents Phase 4
32 Nicotinic Acids Phase 4
33 Hormone Antagonists Phase 4
34 glucocorticoids Phase 4
35 Hormones Phase 4
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
37 Mitogens Phase 4
38 Endothelial Growth Factors Phase 4
39 Antiparasitic Agents Phase 4
40 Antimalarials Phase 4
41 Antiprotozoal Agents Phase 4
42 Tripterygium Phase 4
43 Cholestyramine Resin Phase 4
44 Anesthetics, Local Phase 4
45 Anesthetics Phase 4
46 Anti-Arrhythmia Agents Phase 4
47 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
48 Sodium Channel Blockers Phase 4
49 insulin Phase 4
50 Insulin, Globin Zinc Phase 4

Interventional clinical trials:

(show top 50) (show all 709)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
3 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
4 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
5 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
6 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
7 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
8 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
9 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
10 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
11 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
12 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
13 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
14 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
15 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
16 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
17 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
18 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
19 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
20 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
21 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
22 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
23 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
24 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
25 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
26 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
27 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
28 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
29 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
30 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
31 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
32 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
33 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
34 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
35 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
36 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
37 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
38 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
39 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
40 Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® Completed NCT00127842 Phase 4 Etanercept
41 A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis. Completed NCT00245960 Phase 4 etanercept
42 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
43 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
44 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
45 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
46 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks Completed NCT02798211 Phase 4 Secukinumab;Secukinumab
47 TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile Completed NCT00432406 Phase 4 Infliximab;Etanercept
48 Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab? Completed NCT01465438 Phase 4 Adalimumab
49 Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases Completed NCT00462072 Phase 4 Infliximab
50 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib

Search NIH Clinical Center for Spondyloarthropathy 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Auranofin
Aurothioglucose
Betamethasone
Bupivacaine
Celecoxib
Corticotropin
Cortisone acetate
Dexamethasone
Diclofenac
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Etanercept
Flurbiprofen
Hydrocortisone
Ibuprofen
Ibuprofen
Indomethacin
Infliximab
Ketoprofen
Meclofenamic acid
Methylprednisolone
Naproxen
Naproxen
Naproxen sodium
Piroxicam
Piroxicam
Prednisolone
Prednisone
Ranitidine
Secukinumab
solufenum
Sulindac
Tetracosactide
Tolmetin
Triamcinolone

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spondyloarthropathy 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells to treat ankylosing spondylitis
Embryonic/Adult Cultured Cells Related to Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: spondylitis, ankylosing

Genetic Tests for Spondyloarthropathy 1

Genetic tests related to Spondyloarthropathy 1:

# Genetic test Affiliating Genes
1 Ankylosing Spondylitis 29 HLA-B

Anatomical Context for Spondyloarthropathy 1

MalaCards organs/tissues related to Spondyloarthropathy 1:

41
Bone, Eye, T Cells, Testes, Lung, Heart, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spondyloarthropathy 1:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Spondyloarthropathy 1

Articles related to Spondyloarthropathy 1:

(show top 50) (show all 13081)
# Title Authors PMID Year
1
Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. 38 8 71
8053961 1994
2
Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. 9 38 8
10861282 2000
3
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. 38 8
21743469 2011
4
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. 38 8
20062062 2010
5
Association of chromosome 2q36.1-36.3 and autosomal dominant transmission in ankylosing spondylitis: results of genetic studies across generations of Han Chinese families. 38 8
19416804 2009
6
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. 38 8
17952073 2007
7
Ankylosing spondylitis. 38 8
17448825 2007
8
Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. 38 8
15051216 2004
9
Identification of major loci controlling clinical manifestations of ankylosing spondylitis. 38 8
12905477 2003
10
Chronic synovitis and HLA B27 in patients with severe haemophilia. 38 71
12648975 2003
11
Ankylosing spondylitis, HLA B27, and beyond. 38 8
9519942 1998
12
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. 38 8
9336417 1997
13
The sex ratios of probands and of secondary cases in conditions of multifactorial inheritance where liability varies with sex. 38 8
1999831 1991
14
Relative role of genetic and environmental factors in disease expression: sib pair analysis in ankylosing spondylitis. 38 8
2912465 1989
15
Complete sequence of HLA-B27 cDNA identified through the characterization of structural markers unique to the HLA-A, -B, and -C allelic series. 38 8
3485286 1986
16
Ankylosing spondylitis is part of a multifactorial syndrome: hereditary multifocal relapsing inflammation (HEMRI). 38 8
6332689 1984
17
Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. 38 8
6606431 1983
18
Family studies in Bechterew's syndrome (ankylosing spondylitis) III. Genetics. 38 8
6604602 1983
19
HLA B27 and the genetics of ankylosing spondylitis. 38 8
107868 1978
20
Histocompatibility typing and the counseling of families with ankylosing spondylitis. 38 8
657578 1978
21
HLA B27 in ankylosing spondylitis in India. 38 8
68310 1977
22
Striking prevalence of ankylosing spondylitis in "healthy" w27 positive males and females. 38 8
126380 1975
23
HL-A27 and ankylosing spondylitis in B.C. Indians. 38 8
1185744 1975
24
Ankylosing spondylitis and HL-A. A genetic disease plus? 38 8
1130424 1975
25
Ankylosing spondylitis and HL-A 27. 38 8
4123836 1973
26
High association of an HL-A antigen, W27, with ankylosing spondylitis. 38 8
4688372 1973
27
Human lymphocyte antigen association in ankylosing spondylitis. 38 8
4694299 1973
28
Genetics of ankylosing spondylitis. 38 8
6082899 1967
29
A family study of rheumatoid (ankylosing) spondylitis. 38 8
14454080 1962
30
Hereditary factors in rheumatoid arthritis and ankylosing spondylitis. 38 8
13869952 1961
31
Ankylosing spondylitis in two families showing involvement of female members only. With a search for linkage to genes determining blood group antigens. 38 8
14411096 1960
32
Heredity in ankylosing spondylitis. 38 8
13650428 1959
33
The inheritance of spondylitis rhizomelique (ankylosing spondylitis) in the K. family. 38 8
14783304 1950
34
Increased risk of ankylosing spondylitis after Mycoplasma pneumonia: A Nationwide population-based study. 38 17
31277086 2019
35
Acquired pure red cell aplasia in a patient with ankylosing spondylitis- a case report and literature review. 38 17
31277118 2019
36
Clinical application of diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing the clinical curative effect of early ankylosing spondylitis. 38 17
31096431 2019
37
HLA-B27 lacking associated beta2-microglobulin rearranges to auto-display or cross-display residues 169-181: a novel molecular mechanism for spondyloarthropathies. 8
15388324 2004
38
Significant linkage to spondyloarthropathy on 9q31-34. 8
15234954 2004
39
Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. 8
11762681 2001
40
The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies. 8
10857795 2000
41
HLA-B27 and spondyloarthropathy: value for early diagnosis? 8
7562959 1995
42
HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. 8
7791441 1995
43
Familial aggregation of undifferentiated spondyloarthropathy associated with HLA-B7. 8
7702399 1995
44
A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. 8
8415702 1993
45
Autosomal dominant spondyloarthropathy: no linkage to the type II collagen gene. 8
2300126 1990
46
Autosomal dominant spondyloarthropathy. 8
2927470 1989
47
Progressive ankylosis in mice. An animal model of spondylarthropathy. I. Clinical and radiographic findings. 8
3190783 1988
48
Progressive ankylosis, a new skeletal mutation in the mouse. 8
7276519 1981
49
Joseph J. Bunim Memorial Lecture. HLA-B27 and the inheritance of susceptibility to rheumatic disease. 8
782462 1976
50
The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis. 9 38
20111975 2010

Variations for Spondyloarthropathy 1

ClinVar genetic disease variations for Spondyloarthropathy 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 HLA-B HLA-B, HLA-B27 undetermined variant risk factor

Expression for Spondyloarthropathy 1

Search GEO for disease gene expression data for Spondyloarthropathy 1.

Pathways for Spondyloarthropathy 1

Pathways related to Spondyloarthropathy 1 according to KEGG:

37
# Name Kegg Source Accession
1 Antigen processing and presentation hsa04612

Pathways related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 TNFSF11 TNFRSF1B TNFRSF11B TNF TLR4 TAPBP
2
Show member pathways
12.86 TNFRSF1B TNF TLR4 TAPBP HLA-B B2M
3
Show member pathways
12.76 TNFSF11 TNFRSF1B TNFRSF11B TNF NOD2 MMP3
4
Show member pathways
12.61 TNFRSF1B TNF TAPBP IL17A HLA-B CD40LG
5
Show member pathways
12.44 TNFSF11 TNFRSF1B TNFRSF11B TNF TLR4 CD40LG
6
Show member pathways
12.35 TLR4 TAPBP HLA-B B2M
7 12.15 TNFSF11 TNFRSF1B TNF IL17A CD40LG B2M
8 12.14 TNFSF11 TNFRSF1B TNF CD40LG
9 11.87 TNFRSF1B TNF MMP3 IL17A
10 11.84 TNFRSF1B TNF NOD2 MMP3
11 11.77 TNFSF11 TNF TLR4 CD40LG
12
Show member pathways
11.56 TNF MMP3 CD40LG
13
Show member pathways
11.53 TNFSF11 TNFRSF1B TNF CD40LG
14 11.47 TNFRSF1B TNF TLR4
15 11.41 TNF TLR4 CD40LG
16 11.41 TNF MMP3 IL17A CD163
17 11.37 TNFSF11 TNFRSF11B TNF
18 11.18 TNFSF11 TNFRSF1B TNFRSF11B
19 11.11 TNFSF11 TNF IL17A CD40LG
20 11.05 TAPBP HLA-B B2M
21 10.99 TNFSF11 TNF TLR4 MMP3 IL17A
22 10.82 TNFSF11 TNFRSF11B
23 10.74 TNFSF11 TNFRSF11B

GO Terms for Spondyloarthropathy 1

Cellular components related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 TNFSF11 TNFRSF11B TNF MMP3 IL17A CRP
2 integral component of plasma membrane GO:0005887 9.95 TNFSF11 TNF TLR4 HLA-B CD40LG CD163
3 extracellular region GO:0005576 9.65 TNFSF11 TNFRSF1B TNFRSF11B TNF MMP3 IL17A
4 cell surface GO:0009986 9.63 TNF TLR4 NOD2 HLA-B CD40LG B2M
5 phagocytic vesicle membrane GO:0030670 9.43 TAPBP HLA-B B2M
6 MHC class I protein complex GO:0042612 9.32 HLA-B B2M
7 external side of plasma membrane GO:0009897 9.1 TNF TLR4 IL17A CD40LG CD163 B2M
8 plasma membrane GO:0005886 10.21 TNFSF11 TNFRSF1B TNFRSF11B TNF TLR4 NOD2

Biological processes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.92 TNFSF11 TNFRSF1B TNF MMP3 IL17A
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.87 TNFSF11 TNF TLR4 NOD2
3 cellular response to lipopolysaccharide GO:0071222 9.85 TNFRSF1B TNF TLR4 NOD2
4 regulation of inflammatory response GO:0050727 9.78 TNF TLR4 NOD2
5 positive regulation of MAP kinase activity GO:0043406 9.77 TNFSF11 TNF NOD2
6 positive regulation of interleukin-6 production GO:0032755 9.75 TNF TLR4 NOD2
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.73 TNF TLR4 NOD2
8 inflammatory response GO:0006954 9.7 TNFRSF1B TNF TLR4 IL17A CRP CD40LG
9 positive regulation of interleukin-1 beta secretion GO:0050718 9.69 USP50 TLR4 NOD2
10 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.67 TAPBP HLA-B B2M
11 positive regulation of JNK cascade GO:0046330 9.67 TNFSF11 TNF TLR4 NOD2
12 positive regulation of interleukin-8 production GO:0032757 9.65 TNF TLR4 NOD2
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.65 TNFSF11 TNF TLR4 NOD2 CD40LG
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 TNFRSF1B TNF
15 regulation of osteoclast differentiation GO:0045670 9.63 TNFSF11 TNF
16 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.63 TLR4 NOD2
17 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.63 TAPBP HLA-B B2M
18 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.62 TNF TLR4
19 negative regulation of lipid storage GO:0010888 9.62 TNF CRP
20 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.61 HLA-B B2M
21 positive regulation of interleukin-10 production GO:0032733 9.61 TLR4 NOD2 CD40LG
22 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.59 USP50 TLR4
23 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.58 TAPBP B2M
24 positive regulation of osteoclast differentiation GO:0045672 9.58 TNFSF11 TNF IL17A
25 regulation of immunoglobulin secretion GO:0051023 9.54 TNF CD40LG
26 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.5 TLR4 NOD2 IL17A
27 tumor necrosis factor-mediated signaling pathway GO:0033209 9.35 TNFSF11 TNFRSF1B TNFRSF11B TNF CD40LG
28 immune response GO:0006955 9.28 TNFSF11 TNFRSF1B TNF TLR4 TAPBP IL17A

Molecular functions related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF11 TNF CD40LG
2 cytokine activity GO:0005125 9.02 TNFSF11 TNFRSF11B TNF IL17A CD40LG

Sources for Spondyloarthropathy 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....